Morgans, page-22

commercialisation of a device is a less onerous path than that of a drug, though that said, what ipd has achieved is unusual for a small oz biotech. Reading about lymphoedema, there seems little doubt that it is widespread among cancer patients and this represents a large market in itself. Any better diagnosis/ ongoing measuring option for lymphoedema in this critical time for cancer patients will be, I think, welcomed. If you're trying to recover from any form of cancer, advanced diagnosis and early intervention for lymphoedema would seem a given. So, there would be a measure at surgery, then measures post surgery to allow for early intervention, if necessary. Multiple measures per patient - and at a relatively insignificant cost, relative to the cost of the cancer treatment (with apologies for the seemingly aloof cash analysis of what is an awful situation)
Worldwide market for this? I think the thread has already covered that. Difficulty may be balancing different markets, given the $112 rebate - that is, you may not attract other markets if you have to keep the price up to support the (reviewable) rebate.
In any event, I think there will be a big uptake in the device and revenues will roll in. Falling $A doesn't hurt either.
All IMO. Cheers all and well done to long termers
Patienz